According to the Centers for Disease Control and Prevention, the omicron coronavirus subvariants BA.4 and BA.5 now account for an estimated 35 percent of US cases. The subvariants are on a course to reach dominance at a faster clip than their earlier subvariants, including the current subvariant, BA.2.12.1, which is now in decline.
The pair—which share the same mutation in their SARS-CoV-2 spike protein but have differences elsewhere in their genome—are expected to reach dominance “in a few weeks,” Dr. Shishi Luo told Ars. Luo is chief of infectious diseases at Helix, a California-based population genomics and viral surveillance company that works with the CDC to help track emerging coronavirus variants across the country.
It is unclear what lies ahead in this latest phase of the pandemic. What we know so far about the two subtypes is mixed.
bad and good news
When BA.4 and BA.5 were first detected in South Africa in April, it quickly became clear that both could evade immune responses from vaccination and previous infections, even from previous omicron variants. infection.
On Wednesday, Boston researchers published data in the New England Journal of Medicine that reinforced those findings. The latest data found that those who had been vaccinated and boosted had 21-fold lower neutralizing antibody titers to BA.4 and BA.5 compared to the levels of the original version of SARS-CoV-2. And neutralizing antibody levels were also 3.3 times lower than BA.1 levels. Similarly, in people who were previously infected with BA.1 or BA.2 (most of whom were also vaccinated), neutralizing antibody levels against BA.4 and BA.5 were still approximately 3 from BA levels. times less. .1.
Furthermore, a recently posted preprint study found that BA.4 and BA.5 cause more severe disease in hamsters than BA.2 and BA.2.12.1.
But, there is some good news so far: hospitalization data from other countries where BA.4 and BA.5 have already increased – including South Africa – suggest that the variants are associated with more severe disease and hospitalization in humans. Reasons are not being made.
So, with antivirals that are still effective and vaccinations still protecting against serious illness and death, Luo says it’s really not the time to be concerned. “I don’t think it’s necessary,” Luo said of the oncoming wave.
what is next
But, as BA.4 and BA.5 approach dominance in the US – they are the fourth and fifth omicrons to dominate matters this year alone, after BA.1, BA.2, and BA.2.12.1. The Subvariant Has Been Made – The Question At The Looms: What Happens Next?
With the BA.4 and BA.5 originating in South Africa the week before, we had the opportunity to see this next wave come. But, “there is no other form that is growing right now,” Luo said. There are always samples of some virus here and there that have no lineage yet – which could be new forms – but none is picking up speed, infecting increasing numbers of people, he said. Told. This means that BA.4 and BA.5 can enjoy longer reigns than their predecessors in the absence of any incoming usurers.
“But you know, that could change in the next few days,” Luo said. “I wouldn’t put this virus to mutate again and to have yet another wave.”
Federal regulators and vaccine manufacturers are preparing the Omicron subvariant to be with us through at least the fall and winter. The Food and Drug Administration is gearing up to authorize the next generation of vaccines and boosters by fall that could thwart the seasonal boom. The regulator’s expert advisors will meet next week on June 28 to discuss building those next-generation vaccines. The top candidates are those who target Omicron.
Short and long term plans
On Wednesday, Moderna released preliminary top-line data it will present to the FDA, showing that its combination (bicombinant) vaccine targets both the original version of SARS-CoV-2 and the original Omron version of BA.4 and K. can promote protection against B.5. Moderna says the bivalent booster, called mRNA-1273.214, can increase antibody levels against Ba.4 and Ba.5 by up to 6-fold.
“In the face of continued development of SARS-CoV-2, we are very encouraged that mRNA-1273.214, our prime booster candidate for degradation, showed high neutralizing titers against the BA.4 and BA.5 subvariants, representing a contingency.” are a threat to global public health,” Moderna CEO Stephen Bunsell said in a statement. “We will present these data to regulators immediately and are preparing to supply our next generation of bivalent boosters starting in August, ahead of a possible increase in SARS-CoV-2 infections due to the Omicron subvariant starting in August. Huh.”
While Moderna’s short-term outlook is optimistic, Luo is concerned about continued viral evolution and our declining ability to detect new variants. As people try to move past the acute phase of the pandemic, they are collecting fewer samples for testing. “Looking ahead, we have to find out, what [enough samples], … If not, will there be enough people in urgent care, or health systems, or hospitals, where there is an opportunity to take a sample and send it for sequencing? I think a system that does this on a large scale doesn’t exist yet,” Luo said.
While Helix is exploring ways to set up such a monitoring system, Luo says a comprehensive national strategy needs to be created to stay ahead of variants. “Even though, right now, we don’t think there’s another version on the horizon, it appears we need a plan for how we’re going as a country to respond to that,” she said. “We can’t expect it to go away on its own.” In the worst-case scenario that another type arises that fails treatments and vaccines, “we don’t want to go back to square one, do we? We need a plan.”